<DOC>
	<DOCNO>NCT00601510</DOCNO>
	<brief_summary>RATIONALE : Imatinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , capecitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving imatinib together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib give together capecitabine cisplatin treat patient unresectable metastatic stomach cancer .</brief_summary>
	<brief_title>Imatinib , Capecitabine , Cisplatin Treating Patients With Unresectable Metastatic Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerable dose ass safety tolerability imatinib mesylate combination capecitabine cisplatin patient unresectable metastatic gastric cancer . Secondary - To assess preliminary antitumor activity regimen patient . - To assess response regard expression and/or mutation tyrosine kinase receptor PDGF-R c-kit gastric cancer . OUTLINE : This dose-escalation study imatinib mesylate . Patients receive oral imatinib mesylate daily day -4 21 course 1 day 1-21 subsequent course , oral capecitabine twice daily day 1-14 , cisplatin IV day 1 . Courses repeat every 3 weeks* 12 month absence disease progression unacceptable toxicity . NOTE : *First course 25 day . After completion study therapy , patient follow every 3 week .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric cancer Unresectable and/or metastatic disease Incurable conventional multimodality approach interdisciplinary assessment local tumor board Immunohistochemical documentation ckit ( CD117 ) PDGFR overexpression tumor obtainable ( preferably tumor sample take within 6 week study entry ) At least one evaluable site disease accord RECIST criterion No known brain metastasis CNS disorder might alter study compliance may worsen follow therapy PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 3,000/μL ANC ≥ 2,000/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9.0 g/dL Total bilirubin &lt; 2 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Glomerular filtration rate ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment No known document hypersensitivity fluoropyrimidines , tyrosine kinase inhibitor , cisplatin , platinum , respective derivative No gastrointestinal disorder might affect gastrointestinal absorption capecitabine imatinib mesylate ability swallow oral administration capecitabine imatinib mesylate At least 5 year since prior primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer carcinoma situ cervix No concurrent malignant disease No NYHA class IIIIV cardiac disease ( i.e. , congestive heart failure myocardial infarction within past 6 month ) No severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) No know neuropathy , impair hearing , history seizure , and/or psychiatric disorder might alter study compliance may worsen follow therapy No document dihydropyrimidine dehydrogenase deficiency No known chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) No know diagnosis HIV infection serious uncontrolled infection No significant history noncompliance medical regimen inability grant reliable informed consent PRIOR CONCURRENT THERAPY : No chemotherapy investigational agent within past 4 week ( 6 week nitrosoureas mitomycin C ) unless disease rapidly progress No prior radiotherapy ≥ 25 % bone marrow No major surgery within past 2 week No concurrent warfarin acetaminophen Therapeutic anticoagulation use heparin lowmolecular weight heparin allow No concurrent sorivudine relate substances No concurrent anticancer agent , include chemotherapy biologic agents No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>